---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094528"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-08-12T12:05:37+00:00"
generated_at: "2026-08-12T12:10:26.338989+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Definium DT120 ODT Phase 3 Voyage study hits primary endpoint in GAD; HAM-A diff -5.4

## Summary
- Primary endpoint met: HAM-A LS mean change -11.6 vs placebo -6.2, placebo-adjusted -5.4 (p<0.0001, d=0.81).
- Key secondary endpoints met: CGI-S at Week 12 -0.6 (p<0.0001); HAM-A at Week 1 -7.7 (p<0.0001).
- HAM-A response rate (≥50%) 43% vs 16% (p<0.0001); remission rate (≤7) 14% vs 4% (p=0.0222).
- Safety: mild-to-moderate transient AEs, no new signals, no suicidality; mean EoSC time 6.4 hours.
- Panorama GAD topline results expected in September 2026; follows positive Emerge MDD readout in June.

## SEC filing metadata
- accession: 0001104659-26-094528
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-08-12T12:05:37+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000110465926094528/0001104659-26-094528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000110465926094528/tm2622948d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094528
- JSON: https://secwatch.observer/filing/0001104659-26-094528.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.